Literature DB >> 20034087

Speech characteristics in neurofibromatosis type 1.

Lotta Alivuotila1, Jussi Hakokari, Vivian Visnapuu, Anna-Maija Korpijaakko-Huuhka, Olli Aaltonen, Risto-Pekka Happonen, Sirkku Peltonen, Juha Peltonen.   

Abstract

Neurofibromatosis 1 (NF1) is a neurocutaneous-skeletal disorder often accompanied with varying degrees of cognitive and motor problems that potentially affect speech and language. While previous studies have shown that NF1 may be associated with a variety of deviations in the patients' speech, they have not investigated the characteristics in phonetic detail. Our clinical observation that many patients share a distinct voice and manner of speaking led to the primary aim of this study, which was to present a comprehensive description of speech in NF1. A total of 62 patients with NF1 (age range 7-66 years), and a control group of 24 speakers (age range 7-62 years) were evaluated for their speech. The test sessions were recorded and the data were analyzed both by ear and by acoustic measurements. The data were analyzed separately by two trained phoneticians, and a summary was produced after comparing the two independent analyses. Various speech problems were observed among patients with NF1. Individual variation was remarkable, but the deviations were more common and severe in children than in adult patients. In addition, men with NF1 had more speech deviations than women with NF1. Findings include deviations in voice quality, problems in regulating pitch, deviant nasality, misarticulation, and disfluency. We suggest that difficulties in speech, particularly in regulating pitch, may have negative social implications. Our results highlight which components of speech require particular attention in speech therapy for patients with NF1.

Entities:  

Mesh:

Year:  2010        PMID: 20034087     DOI: 10.1002/ajmg.a.33178

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  9 in total

Review 1.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 2.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

3.  Oral soft tissue alterations in patients with neurofibromatosis.

Authors:  Eeva-Mari Jouhilahti; Vivian Visnapuu; Tero Soukka; Heikki Aho; Sirkku Peltonen; Risto-Pekka Happonen; Juha Peltonen
Journal:  Clin Oral Investig       Date:  2011-02-08       Impact factor: 3.573

Review 4.  Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1.

Authors:  Martha Milade Torres Nupan; Alberto Velez Van Meerbeke; Claudia Alejandra López Cabra; Paula Marcela Herrera Gomez
Journal:  Front Pediatr       Date:  2017-10-30       Impact factor: 3.418

Review 5.  Emerging genotype-phenotype relationships in patients with large NF1 deletions.

Authors:  Hildegard Kehrer-Sawatzki; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2017-02-17       Impact factor: 4.132

Review 6.  Craniofacial and oral alterations in patients with Neurofibromatosis 1.

Authors:  Vivian Visnapuu; Sirkku Peltonen; Lotta Alivuotila; Risto-Pekka Happonen; Juha Peltonen
Journal:  Orphanet J Rare Dis       Date:  2018-08-09       Impact factor: 4.123

7.  Neurofibromatosis type 1 of the child increases birth weight.

Authors:  Jussi Leppävirta; Roope A Kallionpää; Elina Uusitalo; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  Am J Med Genet A       Date:  2019-04-24       Impact factor: 2.802

8.  A rare disease and education: Neurofibromatosis type 1 decreases educational attainment.

Authors:  Edvard Johansson; Roope A Kallionpää; Petri Böckerman; Juha Peltonen; Sirkku Peltonen
Journal:  Clin Genet       Date:  2021-01-12       Impact factor: 4.438

9.  Congenital anomalies in neurofibromatosis 1: a retrospective register-based total population study.

Authors:  Jussi Leppävirta; Roope A Kallionpää; Elina Uusitalo; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  Orphanet J Rare Dis       Date:  2018-01-15       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.